CJC-1295 vs Ipamorelin vs MK-677: GH Secretagogues Compared
A three-way comparison of the most popular growth hormone secretagogues: CJC-1295 (GHRH analog), Ipamorelin (selective GHRP), and MK-677 (oral ghrelin mimetic). Covers mechanisms, selectivity, and practical differences.
Last updated: 2026-03-29
| Property | CJC-1295 | Ipamorelin | MK-677 |
|---|---|---|---|
| Evidence Level | Level C | Level C | Level B |
| Regulatory Status | Investigational | Investigational | Investigational |
| Category | Performance & Growth | Performance & Growth | Performance & Growth |
| Administration | Injectable | Injectable | Oral |
| Onset Time | 1-4 weeks (GH elevation) | 15-30 minutes (GH pulse) | 1-2 hours (GH elevation) |
| Half-Life | 6-8 days (with DAC), ~30 min (without DAC) | ~2 hours | ~24 hours |
| Key Mechanism | CJC-1295 works through the following pathway: GHRH receptor agonism: CJC-1295 binds to GHRH receptors on somatotro... | Ipamorelin's mechanism centers on ghrelin receptor activation: GHSR-1a agonism: Ipamorelin binds with high affinit... | MK-677 acts through ghrelin receptor agonism: Ghrelin receptor (GHSR-1a) agonism: MK-677 binds with high affinity ... |
CJC-1295
- Evidence Level
- Level C
- Regulatory Status
- Investigational
- Category
- Performance & Growth
- Administration
- Injectable
- Onset Time
- 1-4 weeks (GH elevation)
- Half-Life
- 6-8 days (with DAC), ~30 min (without DAC)
- Key Mechanism
- CJC-1295 works through the following pathway: GHRH receptor agonism: CJC-1295 binds to GHRH receptors on somatotro...
Ipamorelin
- Evidence Level
- Level C
- Regulatory Status
- Investigational
- Category
- Performance & Growth
- Administration
- Injectable
- Onset Time
- 15-30 minutes (GH pulse)
- Half-Life
- ~2 hours
- Key Mechanism
- Ipamorelin's mechanism centers on ghrelin receptor activation: GHSR-1a agonism: Ipamorelin binds with high affinit...
MK-677
- Evidence Level
- Level B
- Regulatory Status
- Investigational
- Category
- Performance & Growth
- Administration
- Oral
- Onset Time
- 1-2 hours (GH elevation)
- Half-Life
- ~24 hours
- Key Mechanism
- MK-677 acts through ghrelin receptor agonism: Ghrelin receptor (GHSR-1a) agonism: MK-677 binds with high affinity ...
Key Differences
CJC-1295, Ipamorelin, and MK-677 all stimulate the body's own growth hormone (GH) production, but they do so through different receptor pathways, with different pharmacokinetic profiles, and with meaningfully different side effect profiles. Understanding these differences is essential for evaluating which approach is most relevant to specific research or clinical questions.
Receptor Pathways
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH). It acts on GHRH receptors on pituitary somatotroph cells, mimicking the hypothalamus's primary signal to release GH. The defining feature is the Drug Affinity Complex (DAC) modification, which extends its half-life from minutes to 6-8 days by binding to serum albumin. Without DAC (Modified GRF 1-29), the half-life is approximately 30 minutes, producing more pulsatile GH release.
Ipamorelin is a selective pentapeptide agonist of the ghrelin receptor (GHSR-1a), a distinct and complementary GH-releasing pathway. Its defining advantage is selectivity: it strongly stimulates GH while having minimal effects on cortisol or prolactin, unlike older GHRPs such as GHRP-2 and GHRP-6. This makes it the cleanest injectable GH-stimulating peptide available.
MK-677 (Ibutamoren) is a non-peptide, orally bioavailable ghrelin receptor agonist. Despite targeting the same receptor class as Ipamorelin, its oral bioavailability and 24-hour half-life produce sustained, continuous GH elevation rather than discrete pulses. Its dual mechanism also amplifies hypothalamic GHRH secretion.
Pharmacokinetics and Administration
The practical differences are significant. CJC-1295 with DAC requires only weekly subcutaneous injection but produces continuous GH stimulation that may blunt natural pulsatility. CJC-1295 without DAC requires 1-3 daily injections but better preserves pulsatile GH patterns. Ipamorelin requires 1-3 daily subcutaneous injections with a short half-life of approximately 2 hours, producing clean GH pulses. MK-677 is taken orally once daily — no injections, no reconstitution — but produces 24-hour sustained GH elevation with significant appetite stimulation and documented insulin resistance.
Selectivity and Side Effects
Ipamorelin has the most favorable selectivity profile, with minimal cortisol, prolactin, or appetite effects. CJC-1295 also has a relatively clean profile but may cause pituitary desensitization with the DAC version. MK-677, while convenient, carries the most documented side effects: significant appetite increase, water retention, lethargy, and clinically documented insulin resistance with elevated fasting glucose and HbA1c.
Evidence Level
MK-677 has the strongest human evidence base (Level B), with multiple Merck-funded clinical trials in elderly subjects, GH-deficient patients, and Alzheimer's disease. CJC-1295 and Ipamorelin both have Level C evidence (limited human trial data). The CJC-1295 + Ipamorelin combination, though widely used, has no published clinical trial data.
Which Is Better For...?
Sustained GH elevation with reduced injection frequency — CJC-1295 with DAC provides week-long GH stimulation from a single injection, suited for those prioritizing convenience among injectables.
Clean, pulsatile GH release with minimal side effects — Ipamorelin offers the most selective GH stimulation without cortisol, prolactin, or significant appetite effects. Best for those prioritizing a physiological GH pattern.
Oral convenience with no injections required — MK-677 is the only orally bioavailable option, making it practical for those who cannot or prefer not to inject. It also has the most robust clinical trial data.